Baxter International Inc. (NYSE:BAX)‘s stock had its “buy” rating restated by equities research analysts at BMO Capital Markets in a report released on Friday. They currently have a $70.00 price objective on the medical instruments supplier’s stock. BMO Capital Markets’ target price points to a potential upside of 11.95% from the company’s previous close.

A number of other analysts have also issued reports on BAX. Cantor Fitzgerald initiated coverage on Baxter International in a research note on Thursday, June 29th. They set an “overweight” rating and a $70.00 price objective on the stock. Cowen and Company reiterated a “market perform” rating and set a $66.00 price objective (up from $57.00) on shares of Baxter International in a research note on Monday, July 10th. Morgan Stanley reiterated an “underweight” rating and set a $55.00 price objective (up from $52.00) on shares of Baxter International in a research note on Tuesday, July 25th. Barclays PLC boosted their price objective on Baxter International from $64.00 to $70.00 and gave the company an “overweight” rating in a research note on Thursday, July 27th. Finally, Leerink Swann reiterated an “outperform” rating and set a $75.00 price objective (up from $67.00) on shares of Baxter International in a research note on Thursday, July 27th. One research analyst has rated the stock with a sell rating, five have given a hold rating, seven have given a buy rating and two have given a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $65.69.

Baxter International (NYSE BAX) opened at 62.53 on Friday. Baxter International has a 12 month low of $43.13 and a 12 month high of $64.75. The company has a 50 day moving average price of $62.81 and a 200-day moving average price of $59.23. The company has a market cap of $34.07 billion, a PE ratio of 37.94 and a beta of 0.65.

Baxter International (NYSE:BAX) last released its quarterly earnings data on Wednesday, July 26th. The medical instruments supplier reported $0.63 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.57 by $0.06. Baxter International had a return on equity of 14.82% and a net margin of 8.85%. The company had revenue of $2.61 billion for the quarter, compared to analyst estimates of $2.59 billion. During the same period in the previous year, the company posted $0.46 EPS. The firm’s revenue for the quarter was up .8% compared to the same quarter last year. Equities analysts predict that Baxter International will post $2.39 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Baxter International Inc. (BAX) Given “Buy” Rating at BMO Capital Markets” was reported by American Banking News and is owned by of American Banking News. If you are reading this news story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark law. The original version of this news story can be read at https://www.americanbankingnews.com/2017/10/13/baxter-international-inc-bax-given-buy-rating-at-bmo-capital-markets.html.

In other Baxter International news, SVP Giuseppe Accogli sold 12,670 shares of the company’s stock in a transaction dated Thursday, August 17th. The stock was sold at an average price of $60.96, for a total value of $772,363.20. Following the transaction, the senior vice president now directly owns 33,286 shares in the company, valued at approximately $2,029,114.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director John D. Forsyth sold 9,440 shares of the company’s stock in a transaction dated Friday, August 25th. The stock was sold at an average price of $61.76, for a total value of $583,014.40. Following the completion of the transaction, the director now owns 32,444 shares in the company, valued at $2,003,741.44. The disclosure for this sale can be found here. Insiders sold a total of 35,050 shares of company stock worth $2,158,587 over the last 90 days. Corporate insiders own 0.05% of the company’s stock.

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Park National Corp OH increased its stake in Baxter International by 18.9% in the 3rd quarter. Park National Corp OH now owns 10,969 shares of the medical instruments supplier’s stock worth $688,000 after acquiring an additional 1,746 shares during the last quarter. Griffin Asset Management Inc. bought a new position in Baxter International in the 2nd quarter worth about $457,000. Achmea Investment Management B.V. increased its stake in Baxter International by 15.3% in the 2nd quarter. Achmea Investment Management B.V. now owns 94,282 shares of the medical instruments supplier’s stock worth $5,706,000 after acquiring an additional 12,537 shares during the last quarter. USA Financial Portformulas Corp bought a new position in Baxter International in the 2nd quarter worth about $510,000. Finally, Farmers National Bank increased its stake in Baxter International by 42.4% in the 2nd quarter. Farmers National Bank now owns 8,408 shares of the medical instruments supplier’s stock worth $509,000 after acquiring an additional 2,502 shares during the last quarter. Institutional investors and hedge funds own 83.62% of the company’s stock.

About Baxter International

Baxter International Inc, through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products.

Analyst Recommendations for Baxter International (NYSE:BAX)

Receive News & Ratings for Baxter International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.